6 weeks ago, Tetra announced this (text at the bottom of the page). But we all put this news in our back pocket. I am curious to know more.
Last week, our CEO and distinguished Dr. Chamberland met with the CEO of GW Pharmaceuticals, a company engaged in the research, development and commercialization of cannabinoid prescription drugs using botanical extracts derived from the plant Cannabis Sativa. In short, they are worth $ 137 / share and they had the first cannabinoid drug in the world, (Tetra will be the first in North America). So they met and the text showed the difficulty of breaking into a cannabis product. (When we think of ProMetic who is still struggling and delaying us ... Fortunately, she is not in cannabis.) So I was saying that the two CEOs met but the text only spoke of the difficulty of breaking into a cannabinoid product. If I mention that, there was a CEO discussion and something could happen later. Remember the discussion between Aphria and Shoppers Drug Mart (Pharmaprix in Quebec), all we had known or seen was Vic's smile coming out of the meeting. A few weeks ago Aphria announced that these products would be on Shoppers' shelves. Not all meetings lead to positive results, but I wonder why they announced that they met without unpacking anything. There are several meetings between CEOs of different companies and we do not know because they are not necessarily publicized. Something is questioning me in this secret meeting.
Tetra has 3 great mysteries
1) The international distributor (not yet) announced.
2) The important discovery allowing patent protection
3) The meeting with the CEO of GW Pharma
Tetra Bio-Pharma, you intrigue me. I like this company.
Tetra Bio-Pharma in the process of filing a patent application that exceeds its original data protection assumption for its PPP001
V.TBP | December 6, 2018
ORLEANS, Ontario, December 6, 2018 (GLOBE NEWSWIRE) - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE: TBP) (OTCQ: TBPMF), a leader in drug discovery at Cannabinoid base and development announced that it was filing a patent application for its PPP001 drug product. Tetra's research has led to an important discovery for patent protection.
"This patent application, if accepted, would give Tetra the full protection of its prescription drug PPP001. This will put PPP001 in the same category as any other innovative prescription drug, "said Dr. Guy Chamberland, CEO and CSO of Tetra Bio-Pharma. "We recognize the inherent value of our intellectual property and the need to seek out appropriate patents, to the extent possible, to protect our shareholders' investments in the company."